Special access to ubamatamab for serious conditions
Treatments studied
Part of Cancer clinical trials.
This is a special access program that lets you try an experimental medicine called ubamatamab when no standard treatments are working. Because it is a compassionate-use program, it is only for people with few or no other options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a serious or life-threatening condition that standard treatments haven't helped.
- No alternative treatment is available for you.
- You are not eligible for any other clinical trial for your condition.
- Your doctor must agree to help you apply for this program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy (ubamatamab) alone or with another drug (REGN7075) for people with advanced or metastatic non-small cell lung cancer that has gotten worse after standard treatment. It aims to see if targeting MUC16, a substance found on some cancer cells, can help control the cancer.
This early-phase study tests ubamatamab, a cancer-targeting antibody, given by itself or with cemiplimab. It is meant to treat adults whose cancer has come back and who may not have other good standard options left.
This trial tests an investigational drug called sacituzumab tirumotecan for a rare and aggressive type of kidney cancer called renal medullary carcinoma (RMC) or a related variant. The drug is designed to target and deliver treatment directly to cancer cells. The study aims to see if it can shrink tumors or slow the disease in people who have already tried other treatments.
This trial tests adding a new drug, ubamatamab, to standard chemotherapy for advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if this combination is safe and effective.
This program provides early access to an experimental medicine called vonsetamig for people with serious conditions who have no other treatment options. It is only available on a case-by-case basis through a special request process.
This trial tests an investigational cell therapy called UB-VV500 combined with rapamycin, a drug that may help the therapy work better. It is for people whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to see if this combination is safe and effective.
Hear when a new Epithelioid Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.